Clearmind Medicine Inc. (CMND) — Clearmind Medicine announced publication of an international patent application for a novel therapy targeting weight loss and fatty-liver disease, extending the intellectual-property estate around its psychedelic-derived MEAI platform beyond alcohol use disorder.
The filing broadens Clearmind's potential addressable indications. IP expansion is a recurring value driver for small psychedelic-adjacent biotechs seeking partnering optionality.
Source: globenewswire.com
For the rest of that week's sector news, read our week in review.